Safety Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC) in Patients With Advanced Malignant Solid Tumors

  • STATUS
    Recruiting
  • participants needed
    69
  • sponsor
    Tasly Tianjin Biopharmaceutical Co., Ltd.
Send
Updated on 16 February 2024
See if I qualify

Summary

This open, dose-escalation and extended PhI/IIa clinical trial aims to evaluate the safety, tolerability of T601 as a single-agent as well as combined with prodrug 5-FC to treat patients with advanced malignant solid tumors and to explore the pharmacokinetic characteristics of T601, 5-FC, 5-FU, FBAL, which includes PhI study of dose-escalation study and Ph IIa study of extending study.

Description

Preclinical studies have confirmed that the combination of T601 and 5-FC can not only enhance the anti-tumor effect, but also reduce the toxicity of T601. Considering the risks and benefits of participants of the clinical trial, the protocol design is divided into 4 parts:

Part 1: dose-escalation study of single-dose of T601 to evaluate the safety and tolerability of T601 and to determine the MTD;

Part 2: dose-escalation study of single-dose of T601 combined with predrug 5-FC, to evaluate the safety and tolerability of the treatment of single dose of T601 combined with predrug 5-FC and to determine the MTD of single dose of T601 when combing with 5-FC;

Part 3: dose-escalation study of multiple-dose of T601 combined with predrug 5-FC, to explore the safety and tolerability of the treatment of multiple dose of T601 combined with predrug 5-FC and to determine the MTD of multiple dose of T601 when combing with 5-FC, also to determine the RP2D (recommended dose for Phase II Trial);

Part 4: extending study of multiple-dose of T601 combined with predrug 5-FC, to evaluate the efficacy of the treatment of multiple-dose of T601 combined with predrug 5-FC in patients with various specific tumors and to evaluate the ORR, DCR and PFS according to the RECIST v1.1.

Details
Condition Advanced Malignant Solid Tumors
Age 18years - 75years
Treatment T601, T601+5-FC
Clinical Study IdentifierNCT04226066
SponsorTasly Tianjin Biopharmaceutical Co., Ltd.
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Male or female, aged 18 years and 75
Part1-Part3: histological or cytological confirmed advanced malignant solid tumors patients who have received standard therapeutic options in previous treatment and now there's no standard therapy available; Part4: patients with gastric cancer, pancreatic cancer and hepatocellular carcinoma will be enrolled in Phase IIa Clinical Trial
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Expected survival of at least 3 months
Patient presenting with at least one evaluable lesion according to RECIST 1.1 in Part1-Part3; patient presenting with at least one measurable lesion according to RECIST 1.1 in Part4
Adequate blood system function, liver function and kidney function
ANC1.5109/LPLT80109/LHb90 g/L
TBIL1.5ULNALT3ULNAST3ULN (Patients with liver metastasis or liver cancer ALT5ULNAST5ULN)
Cr1.5ULN, creatinine clearance50mL/min (calculate according to Cockcroft-Gault Formula)
APTT1.5ULNPT1.5ULNINR1.5ULN
Fertile eligible patients (male and female) must agree to use highly effective method of contraception (i.e. hormone or barrier method or abstinence) during clinical trial and for a minimum of 12 weeks after the last administration of T601; negative blood pregnancy test for women of childbearing potential (WOCBP) within 7 days before enrollment
Give informed consent to the study prior to the test and voluntarily sign a written informed consent

Exclusion Criteria

Received chemotherapy, radiation, biotherapy, endocrine therapy, immunotherapy and other anti-tumor treatments within 4 weeks prior to T601 treatment initiation, except for the following items
Received nitrosourea or mitomycin C within 6 weeks before T601 treatment
initiation; Orally taken fluorouracil and small-molecule targeted drugs within
weeks before T601 treatment initiation or within 5 half-lives of the above
drugs (subject to whichever is longer); Received the Chinese medicines with
anti-tumor indications within 2 weeks before T601 treatment initiation
\. Prior participation in another clinical study involving an IMP with last
intake within 4 weeks prior to T601 treatment initiation
\. Received major organ surgery (excluding needle biopsy) or severe trauma
within 4 weeks prior to T601 treatment initiation
\. The adverse reactions of previous anti-tumor therapy have not yet returned
to CTCAE 5.0 1 (except the toxicity that the investigator judged as no safety
risk, such as hair loss)
\. With clinical symptoms of brain metastasis, spinal cord compression, and
cancerous meningitis, or other evidence indicates that the metastasis of the
patient's brain and spinal cord has not been controlled, and the investigator
judged that the patient was not suitable for inclusion. Patients with clinical
symptoms suspected of cerebral or pia mater disease should be excluded by
CT/MRI examination
\. Uncontrolled bacterial, viral or fungal infections requiring systematic
treatment
\. History of immunodeficiency, including positive HIV antibody test
\. Active chronic hepatitis B (HBV-DNA higher than the lower limit of
detection), hepatitis C antibody positive
\. Patients who are unable to swallow oral drugs
\. History of serious cardiovascular and cerebrovascular diseases
Ventricular arrhythmias requiring clinical intervention
Acute coronary syndrome, congestive heart failure, stroke or other class III or above cardiovascular events within 6 months
New York Heart Association (NYHA) cardiac function grade II or Left Ventricular Ejection Fraction (LVEF) <50%
Hypertension uncontrolled by standard treatment
Skin diseases that need systematic treatment
Patients who need long-term use of glucocorticoids (prednisone>10 mg/d or equivalent dose of the same drug) or other immunosuppressive agents during the study period or within 14 days before initiation of T601; Exceptions: local, ocular, intra-articular, intranasal, and inhaled glucocorticoid therapy; Short-term use of glucocorticoids for preventive treatment (e.g. prevention of contrast agent allergy)
History of severe systemic reaction or side-effect after vaccinia vaccine injection
Known hypersensitivity to 5-FC or intolerance to 5-FC treatment
Known alcohol or drug dependence
Mental disorders or patients unable or unwilling to comply with the protocol requirements
Pregnant or lactating female patients
Patients who, as determined by the investigator, have other serious systemic diseases or laboratory abnormalities or other reasons, are not eligible to participate in this clinical trial
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.